Chemotherapy can damage the kidneys, and for certain drugs the risk is substantial. Cisplatin, one of the most widely used and effective cancer-fighting agents, is also one of the most reliably kidney-toxic medications in medicine. But cisplatin is far from alone. Different classes of cancer treatment injure the kidneys through different mechanisms, from crystal deposits blocking the tubules to immune reactions inflaming kidney tissue. The good news is that oncology teams have a growing toolkit for reducing this risk, and understanding what puts your kidneys in danger is the first step toward protecting them.
Why the Kidneys Are Especially Vulnerable During Cancer Treatment
Your kidneys filter roughly 180 liters of blood every day, concentrating waste products for excretion. That filtering job means they encounter drugs at much higher concentrations than most other organs do. When a chemotherapy drug travels through the bloodstream, the kidneys pull it out of circulation and concentrate it in the renal tubules, the tiny tubes where urine is formed. The cells lining those tubules absorb the drug at doses that can overwhelm their ability to cope.
Several patient-level factors make this worse. Pre-existing kidney disease, older age, and dehydration all amplify the damage. So does the simultaneous use of other kidney-stressing medications like certain antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and iodinated contrast dyes used in imaging scans.1Nephrology Dialysis Transplantation. Nephrotoxicity of anticancer treatment Oncologists weigh these factors before every treatment cycle, but the interplay between cancer treatment and kidney health is complex enough that a dedicated subspecialty, onco-nephrology, has emerged to manage it.2Nephrology Dialysis Transplantation. Onco-nephrology: a decalogue
Cisplatin and Its Distinctive Pattern of Kidney Injury
Cisplatin deserves its own discussion because it remains the single biggest nephrotoxic offender in oncology. It is a backbone treatment for cancers of the lung, head and neck, bladder, ovaries, and testes, and it is extremely effective. The problem is that it accumulates in the proximal tubule cells of the kidney at concentrations roughly five times higher than in the blood. The damage it causes is cumulative and dose-dependent: each additional cycle of cisplatin adds to the injury from the last one.3PubMed Central. Pathophysiology of cisplatin-induced acute kidney injury
The injury involves several overlapping processes. The drug triggers oxidative stress, inflammation, and direct death of tubular cells through both necrosis and a more controlled form of cell death. Blood vessels within the kidney also sustain damage, reducing blood flow to the organ. The result can be acute kidney injury, where kidney function drops sharply over hours to days, often requiring dose reduction or even stopping the drug entirely.3PubMed Central. Pathophysiology of cisplatin-induced acute kidney injury The risk factors that worsen cisplatin nephrotoxicity include the total cumulative dose, how often cycles are given, prior cisplatin exposure, and the simultaneous use of other nephrotoxic agents like aminoglycoside antibiotics or NSAIDs.1Nephrology Dialysis Transplantation. Nephrotoxicity of anticancer treatment
Other Chemotherapy Drugs That Threaten Kidney Health
Cisplatin gets the most attention, but several other cancer drugs damage the kidneys through entirely different routes. Knowing which drug causes which type of injury matters because the prevention and management strategies differ.
Methotrexate and Crystal Blockages
High-dose methotrexate, used for certain lymphomas and leukemias, can crystallize inside the renal tubules. These needle-shaped crystals physically obstruct the flow of urine at the microscopic level, leading to a sudden drop in kidney function. The condition is called crystalline nephropathy. In most cases the injury is reversible once the drug is cleared from the body, but the acute episode can be alarming: kidney function can deteriorate rapidly even when preventive measures like aggressive hydration and urine alkalinization have been taken.4PubMed Central. Crystalline Nephropathy With High-Dose Methotrexate in a Patient With Primary CNS Lymphoma: A Case Report
Ifosfamide and Tubular Dysfunction
Ifosfamide, commonly used in sarcomas and some pediatric cancers, can cause a broad dysfunction of the proximal tubule known as Fanconi syndrome. In this condition the tubules lose the ability to reabsorb essential substances they normally reclaim from the urine. Patients develop sugar in the urine despite normal blood glucose, lose phosphate and other electrolytes, spill small proteins, and develop metabolic acidosis.5PubMed Central. Ifosfamide as a Cause of Fanconi Syndrome Cisplatin can also cause Fanconi syndrome, though ifosfamide is more strongly associated with it.6QJM: An International Journal of Medicine. Drug-induced renal Fanconi syndrome In pediatric cancer patients, ifosfamide and doxorubicin were found to have a statistically significant association with kidney-related long-term side effects, and cumulative dose mattered.7PubMed Central. Chemotherapy induced kidney and urinary tract related complications
VEGF-Targeting Drugs and Glomerular Injury
Newer targeted therapies that block vascular endothelial growth factor (VEGF) can harm a different part of the kidney entirely. These drugs, including bevacizumab, work by cutting off the blood supply that tumors need to grow. But VEGF also plays a housekeeping role in the tiny filtering units of the kidney called glomeruli. When VEGF is suppressed there, the glomeruli can develop a condition called thrombotic microangiopathy, where small blood clots form in the kidney’s capillaries and damage the filtering membrane. Research in both patients and animal models has confirmed that this injury is a direct consequence of VEGF suppression within the kidney.8PubMed Central. VEGF inhibition and renal thrombotic microangiopathy
Immune Checkpoint Inhibitors
Immunotherapy drugs, which have transformed the treatment of melanoma, lung cancer, and many other malignancies, can cause a type of kidney inflammation called acute interstitial nephritis. Unlike the direct toxic injury from cisplatin, this damage is driven by the patient’s own immune system. The drugs work by releasing the brakes on immune cells so they can attack cancer more effectively, but sometimes those unleashed immune cells also attack healthy kidney tissue. Research using advanced tissue-mapping techniques has shown that CD8+ T cells in the kidney release signals that trigger a chain of inflammatory events, reducing the tubular cells’ ability to function normally.9PubMed Central. Spatial Transcriptomics Identify T Cell-Driven Mechanisms of Kidney Damage in Immune Checkpoint Inhibitor-Associated Acute Interstitial Nephritis Managing this requires stopping or pausing the immunotherapy and often giving steroids to calm the immune response, which is a fundamentally different approach than managing cisplatin toxicity.
Tumor Lysis Syndrome and Indirect Kidney Damage
Sometimes the kidneys get hurt not by the drug itself but by what the drug does to the cancer. When chemotherapy is very effective at killing cancer cells quickly, especially in fast-growing blood cancers like certain leukemias and lymphomas, the dying cells dump their contents into the bloodstream all at once. The breakdown products of DNA get converted to uric acid, which can crystallize in the kidneys and block them. This is called tumor lysis syndrome, and it represents a medical emergency.10American Journal of Kidney Diseases. Tumor Lysis Syndrome: A Nephrologist’s Perspective The kidney failure here is not caused by the chemotherapy being toxic to kidney cells; it is caused by the chemotherapy being too good at its primary job. Preventive strategies include aggressive hydration and drugs that lower uric acid levels before treatment begins in patients considered at high risk.
Catching Kidney Damage Early
One of the frustrating realities of chemotherapy-related kidney injury is that the standard blood test used to track kidney function, serum creatinine, is slow to rise. By the time creatinine clearly jumps, meaningful damage has often already occurred. Research into newer biomarkers is trying to close that gap. Urinary markers like NGAL, KIM-1, and IL-18 can signal kidney tubule injury at an earlier stage. In patients receiving cisplatin, a doubling of at least one of these markers was common and frequently occurred without any detectable rise in creatinine, suggesting that subclinical kidney injury happens more often than standard labs reveal.11PubMed Central. The Value of Urinary NGAL, KIM-1, and IL-18 Measurements in the Early Detection of Kidney Injury in Oncologic Patients Treated with Cisplatin-Based Chemotherapy
These biomarkers are not yet part of routine clinical practice in most cancer centers, but awareness is growing. If you are receiving cisplatin or another high-risk drug and notice changes in urine output or color, or if you feel unusually fatigued or nauseated between cycles, bring it up with your oncology team. They may order additional labs beyond the standard creatinine check.
How Oncologists Protect Your Kidneys
Prevention is far more effective than trying to repair kidney damage after it happens. Once chemotherapy-induced acute kidney injury is established, treatment options are largely supportive, meaning electrolyte management and dialysis if things get severe enough.12Frontiers in Nephrology. Chemotherapy-induced acute kidney injury: epidemiology, pathophysiology, and therapeutic approaches That makes the strategies used before and during treatment critical.
Aggressive Hydration
The single most established kidney-protection strategy during cisplatin treatment is intravenous hydration. Flooding the kidneys with fluid dilutes the drug concentration in the tubules and speeds its transit through the kidney, giving it less time to do damage. Hydration protocols vary between institutions, but most involve several liters of saline given before, during, and after each cisplatin infusion. Some centers also use shorter hydration protocols for lower cisplatin doses, though the minimum effective volume is still debated.
Magnesium Supplementation
Adding intravenous magnesium to hydration protocols is one of the more compelling protective strategies to emerge in recent years. Cisplatin causes magnesium wasting through the kidneys, and low magnesium levels appear to make the tubular cells more vulnerable to injury. In one study of head and neck cancer patients, those who received magnesium-supplemented hydration lost far less kidney function after two cycles of cisplatin compared to those who received standard fluid alone, and magnesium supplementation was the only independent predictor of protection in the analysis.13PubMed Central. Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer
A larger study published in JAMA Oncology reinforced this finding. Among nearly 14,000 cisplatin treatment encounters, patients who received IV magnesium had about 20% lower odds of developing cisplatin-associated acute kidney injury compared to those who did not, after adjusting for other factors.14JAMA Oncology. Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury This is a simple, low-risk, and inexpensive intervention, and many cancer centers now include it as part of standard cisplatin protocols.
Dose Adjustment Based on Kidney Function
For patients who already have some degree of kidney impairment before starting treatment, or whose kidney function declines between cycles, oncologists adjust drug doses based on how well the kidneys are filtering. This prevents the drug from accumulating to toxic levels. The adjustments are guided by estimated kidney filtration rates and are specific to each drug.15PubMed Central. Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application Carboplatin, a cisplatin relative that is somewhat gentler on the kidneys, is actually dosed using a formula that directly incorporates kidney function, meaning the kidney’s current capacity determines how much drug is given.
Amifostine
Amifostine is a protective drug that selectively shields normal tissues from cisplatin’s damage without reducing the drug’s effectiveness against tumors. It works by scavenging the destructive molecules cisplatin generates inside cells. Studies have shown it can reverse cisplatin’s nephrotoxicity and its bone marrow suppression.16PubMed. Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity Despite this promise, amifostine is not universally used. It can cause its own side effects, including nausea and drops in blood pressure, and there has been some debate about whether it might interfere with the anticancer effect in specific tumor types. Its use tends to be reserved for situations where the kidney risk is especially high.
Medications That Compound the Risk
One of the most practical things you can do to protect your kidneys during chemotherapy is to be careful about other medications. The list of drugs that can add to chemotherapy’s kidney burden is longer than most patients realize. NSAIDs like ibuprofen and naproxen are particularly concerning. A pharmacokinetic study in cancer patients showed that ibuprofen taken alongside pemetrexed, a chemotherapy used in lung cancer and mesothelioma, led to a 20% increase in pemetrexed exposure and a 16% decrease in the body’s ability to clear it.17AACR Journals. Two Drug Interaction Studies Evaluating the Pharmacokinetics and Toxicity of Pemetrexed When Coadministered with Aspirin or Ibuprofen in Patients with Advanced Cancer That means the drug lingers at higher concentrations, increasing the chance of toxicity. NSAIDs also reduce blood flow to the kidneys, compounding the problem.
Beyond NSAIDs, other common culprits include certain antibiotics (aminoglycosides are the classic example), proton pump inhibitors used for acid reflux, iodinated contrast dye used during CT scans, and bone-targeted therapies like bisphosphonates or denosumab.18PubMed Central. Nephrotoxicity in cancer treatment: An overview If you are undergoing chemotherapy, check with your oncology team before taking any new medication, including over-the-counter painkillers. Acetaminophen (Tylenol) is generally safer for the kidneys than ibuprofen during cancer treatment, though it comes with its own liver-related cautions.
When a Kidney Biopsy Becomes Necessary
In many cases of chemotherapy-induced kidney injury, the cause is obvious from the clinical context: a patient on cisplatin whose creatinine rises predictably after each cycle does not need a biopsy to confirm what happened. But when the picture is unclear, especially with newer targeted therapies and immunotherapy, a kidney biopsy can be invaluable. The pathological patterns seen under the microscope vary by drug class, and identifying the exact type of injury changes the treatment approach. A biopsy might reveal thrombotic microangiopathy from a VEGF inhibitor, interstitial nephritis from an immune checkpoint drug, or tubular necrosis from a cytotoxic agent, each requiring different management.19PubMed Central. Anticancer drug-induced nephrotoxicity: biopsy-proven patterns and outcomes across chemotherapy, targeted therapy, and immune checkpoint inhibitors As the number of cancer drugs with kidney effects grows, biopsies are becoming more rather than less important in guiding clinical decisions.
Long-Term Kidney Health After Cancer Treatment
Surviving cancer is increasingly common, and that has brought a growing focus on what happens to the kidneys years after treatment ends. Cancer survivors exposed to nephrotoxic chemotherapy, stem cell transplants, or kidney surgery for renal cell carcinoma are among those at elevated long-term risk for chronic kidney disease.20PubMed. Chronic Kidney Disease in Cancer Survivors The acute injury from cisplatin, for example, does not always fully reverse. Some patients are left with a permanently lower baseline kidney function, which puts them at greater risk for kidney problems later in life, especially as they encounter the normal age-related decline in kidney capacity.
Pediatric cancer survivors face a particularly long runway for these complications. In one study of children treated with chemotherapy, over half experienced kidney or urinary tract complications. Nephrotoxicity was most likely to appear within the first two years after treatment, while urinary tract problems tended to emerge over a longer period extending up to five years.7PubMed Central. Chemotherapy induced kidney and urinary tract related complications For children who may live another 60 or 70 years after treatment, even modest kidney damage during cancer therapy can compound into serious disease decades later. Long-term survivorship care plans increasingly include periodic kidney function monitoring for this reason.
Dietary Considerations During and After Treatment
Nutrition during chemotherapy is complicated because patients are often nauseated, fatigued, and struggling to eat enough. But there is early evidence that certain dietary patterns may help protect organs during treatment. Animal and preliminary human data suggest that restricting dietary fat, protein, and sodium could reduce the side effects of some chemotherapy drugs on the heart, kidneys, and other organs.21Mediterranean Journal of Nutrition and Metabolism. Nutritional interventions based on dietary restriction and nutrient reductions for the prevention of doxorubicin chemotherapy side effects This does not mean crash dieting during cancer treatment, which could be dangerous. Rather, it means that working with a dietitian to moderate protein and sodium intake could offer some kidney-protective benefit without compromising nutritional adequacy. Clinical trials confirming these effects in humans are still needed, so this falls into the “probably won’t hurt, might help” category rather than an evidence-based standard of care.
Staying well-hydrated between treatment cycles is also straightforward advice that matters more than it might seem. Dehydration is one of the most consistent risk factors for chemotherapy-related kidney damage, and cancer patients are prone to it because of nausea, vomiting, and reduced appetite. Keeping up fluid intake on the days between infusions is something you can control that has a genuine protective effect.
The Rise of Onco-Nephrology
The overlap between cancer care and kidney care has become complex enough that the two fields are formally merging into a new specialty. Onco-nephrologists are kidney specialists who focus specifically on patients with cancer. Their roles include managing acute kidney injury during chemotherapy, adjusting cancer drug dosing for patients with impaired kidneys, handling electrolyte emergencies like tumor lysis syndrome, and monitoring long-term kidney health in survivors. The field has proposed a framework that emphasizes multidisciplinary care teams, integrated clinical guidelines, and clinical trials designed specifically for patients who have both cancer and kidney disease.2Nephrology Dialysis Transplantation. Onco-nephrology: a decalogue If you are receiving a known nephrotoxic chemotherapy regimen, asking whether your cancer center has an onco-nephrology consultation service is a reasonable step, particularly if you have pre-existing kidney issues or have already shown signs of kidney function decline during treatment.